Showing 5941-5950 of 8906 results for "".
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac
- Game Change: The New Global Psoriasis Atlas to Accrue Worldwide PsO Datahttps://practicaldermatology.com/news/game-change-the-new-global-psoriasis-atlas-to-accrue-worldwide-pso-data/2458419/Three global health organizations are joining forces to launch the Global Psoriasis Atlas (GPA), the first-ever worldwide database on psoriasis. The GPA project comes in response to the 2016 World Health Organization (WHO) Global Report on
- Stelara Adds New Approval: Crohn's Diseasehttps://practicaldermatology.com/news/stelara-adds-new-approval-crohns-disease/2458422/The FDA has approved STELARA® (ustekinumab) from Janssen Biotech, Inc., for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticost
- Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDAhttps://practicaldermatology.com/news/regeneron-and-sanofis-dupilumab-biologics-license-application-accepted-for-priority-review-by-fda/2458423/The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD). The application has been given a Prescription
- FDA Approves Humira Biosimilarhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar/2458424/The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: ·  
- Alopecia Areata Breakthrough: Two Studies Suggest JAK inhibitors May Spur Hair Regrowthhttps://practicaldermatology.com/news/alopecia-areata-breakthrough-two-studies-suggest-jak-inhibitors-may-spur-hair-regrowth/2458427/Taken together, two new studies suggest that JAK inhibitors may play a role in treating alopecia areata. Two JAK inhibitors are already approved by the U.S. FDA, XELJANZ® (tofacitinib citrate) for rheumat
- African-American Organ Transplant Recipients at Risk for Skin Cancerhttps://practicaldermatology.com/news/african-american-organ-transplant-recipients-at-risk-for-skin-cancer/2458428/All organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer, according to researchers from Drexel University College of Medicine in Philadelphia. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin
- National Rosacea Society Awards Three New Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-three-new-grants/2458430/The National Rosacea Society (NRS) is funding three new studies in addition to continuing support for two ongoing studies as part of its research grants program. In this round, Luis Garza, MD, an associate professor of dermatology at Johns Hopk
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus